Evidence mapPaperPMID 41540229Full record

ArticleNPJ digital medicine2026

Impact of nurse navigation and mobile app on brain tumor patients receiving oral anticancer therapy.

Caroline Poisson, Adeline Duflot-Boukobza, Delphine Mathivon, Mohamed Khettab, Marie Ferrua, Aude Fourcade, Naïma Lezghed, Frédéric Dhermain, François Lemare, Vanessa Puglisi and 7 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Caroline PoissonDepartment of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. caroline.poisson@gustaveroussy.fr.
Adeline Duflot-BoukobzaDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Delphine MathivonDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Mohamed KhettabMedical Oncology, CHU de la Réunion, 97410, Université de La Réunion, Réunion, France.
Marie FerruaDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Aude FourcadeDepartment of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Naïma LezghedDepartment of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Frédéric DhermainRadiation Oncology Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
François LemarePharmacy Department,, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.
Vanessa PuglisiDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
May AbbasDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Mario Di PalmaDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Florian ScottéDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Etienne MinvielleDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Olivier MirDivision of Interdisciplinary Patient Care Pathways (DIOPP), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
David GuyonDepartment of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Sarah N DumontDepartment of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral anticancer agents (OAAs) are commonly prescribed for patients with primary brain tumors, but adherence can be challenging due to cognitive impairment and discontinuous treatment schedules. This subgroup analysis of the randomized phase 3 CAPRI trial evaluated the impact of a nurse navigator-led intervention combined with a digital platform (web portal and mobile app) versus standard care in patients with primary brain tumors treated with OAAs. The primary endpoint was Relative Dose Intensity (RDI), with secondary endpoints including adherence, toxicity, healthcare utilization, and patient-reported experience. Fifty-one patients were included between October 2016 and May 2019, 63% of whom had glioblastoma. Twenty-six patients received the intervention. RDI was significantly higher in the intervention group compared to the control group (105% ± 12 vs. 97.6% ± 13, p = 0.04). The intervention also resulted in fewer emergency room visits, reduced hospitalizations, greater use of supportive care services, and improved patient-reported experience (all p < 0.05). Remote monitoring allowed early corticosteroid adjustments in cases suggestive of intracranial hypertension, helping to prevent hospitalizations. No significant differences were observed in treatment-related toxicity. These findings suggest that a nurse navigator-led digital intervention can improve care continuity and outcomes in this population and merit further investigation.

Identifiers

PMID41540229
PMCPMC12891475

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.